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Objective:  In this paper we discuss the strategy of active surveillance (AS) as a whole followed by the
implications of its use in the Caribbean.
Methods:  The literature was reviewed with a view to establishing the merits of AS and to identify potential
pitfalls in the application of AS among a primarily black population.
Results:  Active surveillance (AS) has emerged as a viable treatment strategy aimed at reducing overtreat-
ment of indolent disease. However, there have been concerns raised over the applicability of AS among men
of African descent. Black men are at higher risk of aggressive disease and data are emerging which suggest
outcomes may not parallel those of their white counterparts. Recent advances such as multiparametric MRI
and genetic testing have the potential to guide decision making in these men.
Conclusion:  Active surveillance should not be universally rejected in black men and perhaps further study
is needed to determine race-specific recommendations. Until then, discussion with the patient should reflect
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It is well known that localized prostate cancer may pursue a rela-
tively indolent course as autopsy studies have revealed that prostate
cancer may be found in up to 50% of men who died of non-prostate
related causes [1]. In the era of PSA screening, there has been an∗ Corresponding author.
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ncreased detection of early stage and less aggressive tumors and
s a result, many low risk malignancies are therefore over treated.
ctive surveillance has emerged as one strategy to circumvent this.
t involves the identification and close followup of men with low
isk disease – treatment with curative intent is only administered
pon clinical progression or patient request. Active surveillance
as now been included in the guidelines of several major organiza-
ions including the American Urological Association [2], European
ssociation of Urology [3] and the National Comprehensive Cancer
etwork [4].
nd hosting by Elsevier B.V. This is an open access article under the CC
90 S. Persaud et al.
Table  1  Active surveillence inclusion criteria. The Royal Marsden Group (Van As et al.) has less stringent criteria than the others.
Author Clinical stage PSA Gleason grade Positive cores Other
Carter et al., 2007 [7] ≤T2a – ≤6 ≤2 PSAD ≤0.15
Dall’Era et al., 2008 [8] ≤T2a ≤10 ≤6 ≤33%
Berglund et al., 2008 [9] ≤T2a ≤10 ≤6 ≤3 –










































































Soloway et al., 2008 [11] ≤T2a ≤10 
Klotz et al., 2010 [12] – ≤10 
irst described in 1994, and updated in 2004, The Epstein criteria
re used to identify low risk cancers [5,6]. Features of insignificant
isease according to the criteria include – Gleason sum ≤6, PSA
ensity <0.15, no more than 2 cores positive with ≤50% involvement
f any one core and stage ≤T1c. While various selection protocols
re described, criteria from most large centers, with the odd excep-
ion, have a few common features–Gleason score ≤6, Stage ≤T2a
nd PSA ≤10 [7–12] (Table 1). While not a part of surveillance
rotocols at the moment, volume of tumor has been proposed as
nother tool in calculating risk. Data from the European Random-
zed Study of Screening for Prostate Cancer (ERSPC) trial suggest
hat total volume of ≤1.3 cm3 is predictive of low risk disease
13]. However, it has been noted that active surveillance criteria
erform poorly in men of African descent compared to whites
14].
ost centers use either changes in PSA kinetics or adverse patholog-
cal features on biopsy as triggers for intervention. Patient request is
lso an indication for intervention. While no standardized protocol
xists, patients are usually followed with 3–6 monthly PSA mea-
urements and digital rectal examinations [15]. The role of PSA in
ctive surveillance protocols is controversial with several authors,
mong large cohorts, finding little change in PSA kinetics even with
istological evidence of progression [16,17]. Nonetheless, a number
f large institutions still list various derivatives of PSA among their
rimary triggers for intervention. For example, Klotz et al. at the
niversity of Toronto use a PSA doubling time of <3 yrs while the
emorial Sloan Kettering group uses a PSA >10 ng/ml [9,12]. The
oyal Marsden Group uses a PSA velocity of >1 ng/ml/yr as a trig-
er for intervention [10]. Ng et al. demonstrated a PSA velocity of
 ng/ml/yr was significantly associated with an increase in Gleason
core [18].
earing in mind the potential limitations with PSA kinetics, biopsies
re repeated every 1–3 years but may be done as early as 3 months
15]. Data garnered from post prostatectomy specimens in active
urveillance patients have confirmed that a significant proportion
f men are understaged or undergraded and it is estimated that this
isk may be in the order of 20–30% [15]. Progression of Gleason
rade may be ascribed either to tumor de-differentiation or to





Table  2  Outcome data from various active surveillance cohorts.
Institution/author No. treated (%) 
Johns Hopkins/Tosoian et al., 2011 [21] 255 (33) 
USCF/Cooperberg et al., 2011 [22] 113 (30) 
University of Toronto/
Klotz et al., 2010 [12]
135 (30) 
University of Miami/Soloway et al., 2010 [23] 67 (20) 
Royal Marsden/van As et al. [10] 65 (20) ≤6 ≤2
≤6 –
f the two. Adamy and colleagues at Memorial Sloan-Kettering
ancer Center demonstrated that early rebiopsy of men on active
urveillance within 3 months, resulted in upstaging of 35% [19]. In
he PRIAS group the authors also found that 21.5% of men were no
onger eligible for active surveillance following early repeat biopsy
20]. Therefore, one strategy employed by some centers such as
SKCC to combat understaging is the use of early confirmatory
iopsies, usually within 3 months [9]. Pathological progression on
epeat biopsy, that is, increase in Gleason grade, number of positive
ores or percentage of involvement of each core, constitute grounds
or discontinuation of surveillance [15]. It is our practice to rebiopsy
atients at 12 months and we have not adopted the strategy of early
ebiopsy.
s mentioned above progression may be defined as changes in
SA with time or increases in the volume or grade of cancer on
urveillance biopsy. Dall’Era suggests that “progression” may in
act be “reclassification” as more of the prostate is sampled with
urveillance biopsies. Nonetheless, with progression or reclassifica-
ion beyond the initial entry criteria, immediate curative treatment
s offered. Some men may elect treatment even with no change to
heir status [15].
utcome data are available from several large institutional studies
nd are very encouraging for the strategy as a whole. Five-year
urvival approaches 100%, with 20–33% ultimately undergoing
reatment. These results are perhaps best summarized in a tabu-
ar format (Table 2). With the exception of the groups from Miami
nd Johns Hopkins, an analysis of outcomes as a function of race is
ot forthcoming in most series.
here is concern over the applicability of active surveillance
rotocols to our predominantly black population. This concern
s justifiable as data are emerging which suggest that patients
f African ancestry may experience earlier disease progression
hile under surveillance [14]. What is more worrisome is that
hese patients have been noted to have more aggressive disease
t prostatectomy which may compromise long-term cancer related
utcomes. This propensity to progress and progress with aggressive
isease may make curative treatment challenging and seems to go
gainst the whole premise of active surveillance.




























































Active surveillance for prostate cancer 
The burden of prostate cancer mortality is high within the Caribbean
territories. In Jamaica the annual incidence rate has been reported to
be as high as 304 per 100,000 [24]. In Barbados the incidence rate
has been estimated at 160.4 per 100,000 [25] while in Tobago the
prevalence of prostate cancer among men who were screened was
10% [26]. In Trinidad and Tobago prostate cancer is the leading
cause of cancer mortality, accounting for 38% of cancer related
deaths among men (Data, Trinidad and Tobago Cancer Registry).
The Caribbean collectively has the highest prostate cancer mortality
in the world [27].
Correspondingly, the Caribbean has a large black population. In
Jamaica 91% of the population are of African descent [28] while in
Tobago this number is 94% [26]. The increased risk of prostate can-
cer among black men in the Caribbean, likely, reflects an increased
genetic susceptibility of the race as similarly high incidence rates
have been noted in black populations in the United States of America
and the United Kingdom [26,28,29]. In a recent study at our institu-
tion, it was noted that blacks were more likely to present with higher
PSA values – 27.5% of blacks had a PSA greater than 100 ng/ml
compared to 10.6% of Indians (p  < 0.001). Blacks were also more
likely to have higher Gleason scores [30].
The biology of prostate cancers in the black male may place him at
increased risk of progression while on active surveillance. Among
131 men Kim looked at the expression of several biomarkers which
were associated with progression (e.g. Ki67, androgen receptor, and
alpha-methylacyl CoA racemase) and compared them as a function
of race. All markers were expressed at higher levels among blacks
suggesting that their disease may be more biologically aggressive
[31]. In a study of 1056 men, Powell and colleagues reported on
clinicopathological characteristics of subclinical prostate cancer at
autopsy, comparing them to post prostatectomy specimens. These
authors noted that while pathologic findings were similar between
blacks and whites at autopsy, blacks were more likely to have higher
Gleason scores and tumor volume at prostatectomy [32]. These find-
ings led the authors to conclude that prostate cancer may become
aggressive earlier in the black male.
Sanchez-Ortiz and colleagues looked at the post-radical prosta-
tectomy specimens of 37 African–American and 35 white men,
matching them for age, PSA, clinical stage and prostate weight with
all having cT1c disease. The authors demonstrated that that Glea-
son score and tumor volume were significantly higher in black males
[33]. Similarly, in a recent multi-institutional study Ha et al. com-
pared clinicopathological characteristics of black vs. white males
who underwent radical prostatectomy while in an active surveillance
program. Black men were more likely to be upstaged at prosta-
tectomy (≥pT3) than their white counterparts (19.4% vs. 10.1%).
These findings point to the fact that black men may easily be mis-
classified as low risk using current active surveillance protocols
[34].
In a retrospective study, Sundi et al. reported on pathological char-
acteristics among a cohort of 256 African-American and 1473
white men who underwent radical prostatectomy and also satis-
fied the National Comprehensive Cancer Network (NCCN) criteria
for active surveillance. The authors found that African-American
men were more likely to have disease upgrading (27.3% vs. 14.4%)
as well as a higher rate of positive margins (9.8% vs. 5.9%).
African-Americans also had higher Cancer of the Prostate Risk






nalysis African-American race was independently associated with
dverse pathological features [35].
hat are the implications of this data for black men on active surveil-
ance? Of 272 men enrolled in an active surveillance program in
iami 64 progressed. Twenty-four African American men were
nrolled in the study of whom 14 progressed (58.3%) compared to
0 of 225 (22.2%) white males. The rate of progression was almost
 times as great among African American men [36].
ecently, Abern and colleagues at Duke University reported on their
eview of 145 patients in which they investigated the impact on race
n the outcome of patients on active surveillance particularly as it
elated to discontinuation of surveillance for treatment. The cohort
omprised 32 (22%) black men. When adjusted for socioeconomic
tatus and clinical parameters, black race was associated with a
igher rate of discontinuation of active surveillance for treatment,
ith a hazard ratio of 3.08 [37].
t is clear from the body of evidence so far that active surveillance
s a legitimate treatment option in the management of prostate can-
er which can prevent “over treatment” in many men. However,
he data as it relates to the black race point to significant clinical
onsiderations for the black Caribbean man on active surveillance.
or starters, the increased risk of progression while on observation
hould be fully discussed with the patient. He should be counseled
hat outcomes in his race may not parallel those published from large
ctive surveillance cohorts. In addition, Ha suggested that criteria for
ntry in to active surveillance should be amended to reflect the fact
hat black patients are at higher risk of being upgraded and upstaged
t prostatectomy, that is, they are at higher risk of having either
heir disease characteristics underestimated at the time of entry
nto active surveillance programs or of truly developing aggres-
ive disease. The authors suggest more stringent criteria utilizing
 maximum of one core or using a lower PSA cutoff [34]. Given
hat misclassification of risk seems to be greater in this group, Ire-
ashvili and colleagues urge more extensive biopsy protocols along
ith intensified followup for earlier detection of progression [36].
ollowing the publication of Dr Sundi’s paper cited above, the team
t Johns Hopkins also called for the development of race-specific
ntry criteria.
ecently, magnetic resonance imaging has emerged as a poten-
ial adjunct to improve accuracy in classifying men for active
urveillance. Park and colleagues recently reviewed 298 men who
nderwent radical prostatectomy and who fit the PRIAS active
urveillance criteria. Approximately 7% of patients were upstaged
nd 46% were upgraded at surgery; patients with visible disease
ere more likely to have their disease upgraded [38]. Similarly,
n a cohort of 388 men with low risk prostate cancer, Vargas and
olleagues noted that MRI imaging scores, indicative of tumor
isibility, correlated significantly with the risk of upgrading on con-
rmatory biopsy while on active surveillance. That is to say, highly
isible tumors were much more likely to be upgraded on subsequent
iopsy [39]. Margel also found that risk of reclassification was much
ess when no tumor was visualized on MRI [40]. In a small study
hich requires further validation, Stamatakis and colleagues using
orphological and functional characteristics of the lesion on MRI,erived a nomogram which may predict disease reclassification.
umber of lesions, lesion density and lesion suspicion were asso-
iated with disease reclassification [41]. This was a small study of
















































f the study. The use of MRI as part of active surveillance selection
riteria is an evolving field which holds much potential, particularly
o among a population such as ours. The application of MRI in the
aribbean poses a challenge for a region with high disease burden
nd limited access to MRI facilities.
enetic testing as well as serum and urinary biomarkers may in the
uture assist with more accurate stratification of these men. Urinary
CA-3 and the TMPRSS-ERG fusion gene have been studied for this
urpose. Li recently demonstrated that both of these markers were
ssociated with higher volume disease [42]. Klein and colleagues
ave also recently validated a multigene test called the Genomic
rostate Score (GPS) for its ability to more accurately predict men
ith high grade and high stage disease. 17 genes were identified and
ombined to form the GPS algorithm [43]. This is indeed exciting
ut, as with MRI, its application in an often resource poor setting
uch as ours will be a challenge.
lthough active surveillance should not be universally rejected in
lack men, further study is needed to determine race-specific rec-
mmendations. Until then, discussion with the patient should reflect
he potential pitfalls for Black men on active surveillance.
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